Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Ouvert

13.35 0.6

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

13.5

Chiffres clés
By Trading Economics
Revenu	-1.4M -14M
BPA	-0.15
Employés	37
EBITDA	312K -12M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+138.31% upside

Dividendes
By Acuity
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-261M 1.1B
Ouverture précédente	12.75
Clôture précédente	13.35

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 août 2026, 23:51 UTC

Cautious Optimism Surrounds Upcoming South Korea Manufacturing PMI Release Amid Mixed Economic Signals and Regional Trends

2 août 2026, 23:51 UTC

Japan's Upcoming Current Account Release on August 9, 2026, Expected to Reflect Export-Import Balance Amidst Cautiously Optimistic Market Sentiment.

2 août 2026, 23:51 UTC

Correlated Moves

Macro News

Bitcoin is trading higher, influenced by rising crude oil prices and positive tech stock performance. Ethereum's increase also supports Bitcoin's upward movement today.

2 août 2026, 23:31 UTC

Bitcoin and Ethereum rise amid market volatility and geopolitical tensions, as investors brace for potential Fed rate hikes and key economic data releases.

2 août 2026, 23:31 UTC

Bitcoin and Ethereum rise amid market volatility, while momentum trading strategies face significant drawdowns as the Fed's steady interest rates and geopolitical tensions influence investor sentiment.

2 août 2026, 23:31 UTC

Bitcoin and Ethereum rise amid geopolitical tensions and potential U.S. rate hikes, as investors brace for key labor market data.

2 août 2026, 23:31 UTC

Bitcoin and Ethereum rise amid declining momentum trading strategies, while geopolitical tensions and inflation concerns heighten expectations for a potential Federal Reserve interest rate hike.

2 août 2026, 23:21 UTC

Social Media

Correlated Moves

Macro News

Geopolitical tensions and rising fuel prices are driving demand for gold. Gold has gained modestly since Friday, with silver also rising today.

2 août 2026, 23:02 UTC

Correlated Moves

AUD/CAD is higher in after-market trading, reflecting a modest gain since Friday's close and correlating with a rise in AUD/USD.

2 août 2026, 23:01 UTC

Correlated Moves

Gold/JPY is advancing during Sunday’s session, supported by rising gold prices. The pair remains below its 20-day moving average amid ongoing market volatility.

2 août 2026, 23:01 UTC

Correlated Moves

Macro News

EUR/USD rises in after-market trading, reflecting market reactions to potential U.S. monetary policy changes and concerns about a financial crisis linked to AI developments.

2 août 2026, 23:01 UTC

Copper is trading higher during Sunday’s session, maintaining strength despite a slight pullback from earlier gains. It remains above its 20-day moving average.

2 août 2026, 23:01 UTC

GBP/NOK is trading higher in after-market hours, reflecting a shift in trading dynamics despite recent market volatility and being near the lower end of its one-month range.

2 août 2026, 23:01 UTC

Correlated Moves

Silver prices are advancing today, reflecting a broader upward movement in precious metals, despite earlier intraday volatility. Gold's increase may support silver's rise.

2 août 2026, 23:01 UTC

Correlated Moves

Gold/NZD is higher today, recovering from an earlier low and reflecting a similar rise in gold prices since Friday's close.

2 août 2026, 23:01 UTC

Correlated Moves

Silver/CHF is trading higher, recovering from earlier lows and reflecting a strong upward trajectory since Friday's close, in line with rising gold prices.

2 août 2026, 23:01 UTC

Macro News

The Nikkei 225 Index is lower in after-market hours, continuing a decline linked to a weaker yen and potential interest rate hikes amid inflation concerns.

2 août 2026, 23:01 UTC

Correlated Moves

Silver/GBP is trading higher, recovering from an earlier dip. The asset has increased notably since Friday's close, reflecting a strong correlation with gold.

2 août 2026, 23:01 UTC

Correlated Moves

Gold/CAD is trading higher, rebounding from earlier losses amid rising silver prices. Broader market sentiment shows a decline in momentum trading strategies.

2 août 2026, 23:01 UTC

Correlated Moves

The S&P 500 Index is trading higher, continuing a trend of three consecutive positive sessions, supported by gains in the Dow Jones Index.

2 août 2026, 23:01 UTC

Correlated Moves

Silver/JPY is trading higher amid market volatility, reflecting a notable increase. The rise aligns with a gain in gold, indicating a strong correlation.

2 août 2026, 23:01 UTC

Correlated Moves

Silver/SGD is trading higher, reflecting a broader rise in precious metals. Earlier, the asset pulled back but has since rebounded from session lows.

2 août 2026, 23:01 UTC

Correlated Moves

Gold/AUD is rising today, supported by an increase in Gold (XAU/USD). The price remains near the lower end of its one-month trading range.

2 août 2026, 23:01 UTC

Correlated Moves

Gold/CHF is advancing, reflecting gains in Gold (XAU/USD) and macroeconomic factors. Recent market volatility continues to influence investor risk sentiment.

2 août 2026, 23:01 UTC

Correlated Moves

Gold/GBP is trading higher, recovering from an earlier dip amid increased Gold prices and shifts in investor sentiment during market volatility.

2 août 2026, 23:01 UTC

Correlated Moves

Silver/NZD is trading higher, recovering from earlier fluctuations, as gold prices rise. It remains about 1.03% below its 20-day moving average.

2 août 2026, 23:01 UTC

Correlated Moves

Silver/HKD is trading higher today, supported by a rise in gold prices. Earlier, it experienced notable volatility but has since recovered above Friday's close.

2 août 2026, 23:01 UTC

Macro News

The US 5Y Treasury Bond Index is higher, recovering from an early dip amid Federal Reserve discussions on interest rate hikes and inflation concerns.

2 août 2026, 23:01 UTC

Correlated Moves

Silver Ounce vs Euro shows notable gains today, driven by rising gold prices. Earlier, XAG/EUR pulled back from a session high but remains elevated.

2 août 2026, 23:01 UTC

Correlated Moves

Gold/HKD is higher today, reflecting a modest gain since Friday's close amid broader market volatility and heightened investor anxiety.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

138.31% hausse

Prévisions sur 12 Mois

Moyen 31.6 USD 138.31%

Haut 40 USD

Bas 27 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.